GlassScriptPhysician profile
Ramon Moreda
NPI 1205925401
$7,359.86
in general payments reported to CMS, 2019-2025
21 companies · $1,748 in 2025
The $1,748 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,587 · 2020: $664 · 2021: $771 · 2022: $974 · 2023: $767 · 2024: $848 · 2025: $1,748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,522 · Travel and Lodging: $842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,521.61 |
| Travel and Lodging | $841.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,477.70 | 2019-2025 | |
| Amgen INC. | $1,189.71 | 2019-2025 | Evenity, Enbrel, Krystexxa |
| Ucb Sa | $1,141.70 | 2025 | |
| Abbvie INC. | $763.83 | 2019-2025 | |
| Radius Health, INC. | $585.20 | 2019-2024 | |
| Glaxosmithkline, LLC. | $557.47 | 2019-2024 | Benlysta |
| Ucb, INC. | $337.66 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $278.69 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $209.64 | 2021-2023 | Acthar |
| Pfizer INC. | $189.24 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $125.97 | 2024 | Saphnelo |
| Esperion Therapeutics, INC. | $124.49 | 2021 | |
| Novo Nordisk INC | $122.06 | 2021 | |
| Janssen Scientific Affairs, LLC | $101.54 | 2019 | |
| Janssen Biotech, INC. | $43.91 | 2024-2025 | Tremfya |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $30.15 | 2024 | Arcalyst |
| Intuitive Surgical, INC. | $29.02 | 2019 | |
| Ascend Therapeutics US, LLC | $18.00 | 2021 | |
| Medexus Pharma, INC. | $17.10 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $16.78 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramon Moreda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.